Alexandra Gylfe is a founding partner at Nordic Science Investments, a venture capital fund focused on science-based spinouts. With a PhD in cancer genetics from the University of Helsinki and experience as a visiting researcher at Stanford University, she has extensive biotech experience.
Alexandra led the Oncology R&D Team at Human Longevity Inc. in the US, a company that achieved unicorn status under Craig Venter’s leadership. She also served as the Business Development Director of iCAN, a national flagship in research and innovation, where she drove strategic partnerships in Digital Precision Cancer Medicine, and at Helsinki Innovation Services, supporting research commercialization and spinout creation.
She has a strong network in the US biotech sector and a passion for scaling high-quality university spinouts in the Nordics and Baltics.
